Please join us via Zoom, or use this streaming link. Presentations qualify for CME credit. To obtain your CME credit, you will need to use the U of A COM-T CloudCME system.
MDMA Therapy for PTSD
Jennifer Mitchell, PhD
Associate Chief of Staff for Research and Development, SFVAMC
Faculty | Neuroscape
Professor, Departments of Neurology and Psychiatry and Behavioral Sciences
Weill Institute for Neurosciences
University of California San Francisco
Learning Objectives:
- Describe the basic pharmacological actions of MDMA for PTSD.
- Summarize the current research in the field of MDMA medication development.
- Understand the FDA approval process for novel therapeutics.
The educational objective of Psychiatry Grand Rounds is to provide mental health professionals with updates on psychiatric topics with the goals of increasing knowledge, competence, and patient care. Psychiatry Grand Rounds are held on Wednesdays (September-May) from 12 to 1 p.m.
Persons with a disability may request a reasonable accommodation, such as a sign language interpreter, by contacting us at 520-874-4148. Requests should be made as early as possible to allow time to arrange the accommodation.
Accreditation Statement:
The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Relevant Financial Relationships Statement(s):
University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.
| Name | Individual's role in activity | Nature of relationship(s) / Name of inelegible company(s) |
|---|---|---|
| Jordan F Karp, MD | Activity Director | Grant or research support-Janssen (Any division)|Advisor-AifredHealth|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Biogen (Relationship has ended) - 11/27/2023 |
| Marianne Klugheit , MD | Planning Committee Member | Nothing to disclose - 06/03/2024 |
| Kyle Suhr, PhD, Clinical Psychologist | Planning Committee Member | Nothing to disclose - 04/04/2024 |
| Brittany L Pace, MD | Planning Committee Member | Nothing to disclose - 06/03/2024 |
| Denise Rodriguez Esquivel, PhD | Planning Committee Member | Nothing to disclose - 06/03/2024 |
| Elisa Gumm, DO | Planning Committee Member | Nothing to disclose - 06/10/2024 |
| Derek Paul, MD | Planning Committee Member | Nothing to disclose - 06/04/2024 |
|
Jennifer Mitchell, PhD |
Faculty |
Grant or research support-Lykos Therapeutics (Relationship has ended) - 12/12/2024 |